Navigation Links
Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II

ABBOTT PARK, Ill., Jan. 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today it received approval from the U.S. Food and Drug Administration for its fully automated HTLV-I/HTLV-II blood screening test for use on the ABBOTT PRISM instrument. The test is intended for use by laboratories to screen individual donations of blood and plasma for antibodies to human T -- lymphotropic virus Type I and/or human T -- lymphotropic virus Type II (anti-HTLV-I/HTLV-II).

HTLV-I and HTLV-II are closely related but distinct retroviruses associated with several diseases including human T-cell leukemia and neurological disorders, according to the Centers for Disease Control. Screening of the U.S. blood supply for HTLV-I/II began in 1988.

Used in more than 30 countries, the PRISM system also includes four hepatitis tests: a core hepatitis B test (PRISM HBcore), introduced in October 2005; two hepatitis B surface antigen tests (PRISM HBsAg and HBsAg Confirmatory), introduced in July 2006; and a hepatitis C test (PRISM HCV), introduced in July 2007.

"With the ABBOTT PRISM system, we continue to support the infectious disease testing needs of the laboratory while helping them realize greater efficiencies and enhanced operator safety throughout the blood and plasma screening process," said Robert Doss, Ph.D., divisional vice president, diagnostics research and development, Abbott. "The introduction of the PRISM HTLV-I/HTLV-II test reinforces Abbott's role as a leader in ensuring the safety of the world's blood supply."

In 1985, Abbott developed the first HIV blood-screening test approved in the United States. Today, Abbott's infectious disease tests are used thousands of times every day around the globe for blood screening and diagnostic testing. According to the American Association of Blood Banks (AABB), eight million volunteers donate about 15 million units of whole blood each year. Each donated unit of blood is tested for infectious diseases including hepatitis, HIV and other retroviruses.

Important Product Usage and Safety Information

The ABBOTT PRISM HTLV-I/HTLV-II test (human T-lymphotropic virus Types I and II) can be used by laboratory technicians to screen individual donations of blood and plasma for antibodies to human T -- lymphotropic virus Type I and/ or human T -- lymphotropic virus Type II (anti-HTLV-I/HTLV-II). This assay has not been validated for use with pooled specimens. The assay is not intended for use on cord blood specimens or for the laboratory diagnosis of HTLV-I/HTLV-II infection. This product contains human sourced and/or potentially infectious components.


The PRISM instrument consolidates testing into a single system automating many of the manual testing procedures and steps currently used to screen blood. Safety features built into the system help track and monitor each sample throughout the testing process providing documentation and quality control for testing facilities. The PRISM system can run 160 samples per hour, making it possible to test more than 1,200 samples per eight-hour shift.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott to Present at JP Morgan Healthcare Conference
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Abbott Declares 336th Consecutive Quarterly Dividend
4. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
5. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
6. Abbott Scientists Create One Molecule With Two Antibody Functions
7. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
8. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
9. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
10. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
11. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... This fall, ... at competitive events in five states to develop and pitch their BIG ideas to ... from each state are competing for votes to win the title of SAP's Teen ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):